Cost-Effectiveness Analysis of Pembrolizumab for First-Line Treatment in Patients with Persistent, Recurrent, and Metastatic Cervical Cancer in the United States: Results from the Final Analysis of Trial

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy, with or without Bevacizumab for the First-Line Treatment of Pd-L1-Positive Patients with Persistent, Recurrent, or Metastatic Cervical Cancer in France

Unleashing the Power of Social Media Listening: A Promising Tool for Patient-Focused Research

Q-TWiST Analysis Is Back in the Game in Oncology Clinical Trial Analysis: A Recent Trend

Toxicity, Progression-Free Survival, and Quality of Life of Patients Treated with Zanubrutinib Versus Ibrutinib: A Q-TWiST Analysis from the ALPINE Study in Relapsed or Refractory Chronic Lymphocytic Leukemia
